Ladenburg Thalmann’s Christopher S. James initiated coverage of four biotech companies with a Buy rating, given that each has a promising lead drug candidate that is expected to drive growth in the near future.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Achillion Pharmaceuticals (ACHN):